We are live on ! Find out more
STOK icon

Stoke Therapeutics
STOK

97 hedge funds and large institutions have $680M invested in Stoke Therapeutics in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $1.72M | Put options by funds: $1.09M

58% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 26

8% less funds holding

Funds holding: 106 → 97 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

49.74% less ownership

Funds ownership: 104.81% → 55.07% (-50%)

54% less capital invested

Capital invested by funds: $1.49B → $680M (-$811M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
97
Holders Change
-9
Holders Change %
-8.49%
% of All Funds
1.69%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
11
Increased
41
Reduced
26
Closed
20
Calls
$1.72M
Puts
$1.09M
Net Calls
+$634K
Net Calls Change
+$2.1M

Top Buyers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
+$10.5M
2
State Street
State Street
Massachusetts
+$5.57M
3
SFM
Sphera Funds Management
Israel
+$2.91M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.75M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.29M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$26.4M
2
Goldman Sachs
Goldman Sachs
New York
-$14.9M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.33M
4
CAM
Cormorant Asset Management
Massachusetts
-$5.64M
5
BlackRock
BlackRock
New York
-$5.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
76
Meeder Asset Management
Ohio
$47K -$4.67K -132 -9%
PHK
77
Point72 Hong Kong
Hong Kong
$46K +$48.2K +1,363 New
Ensign Peak Advisors
78
Ensign Peak Advisors
Utah
$44K -$154K -4,360 -77%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$44K +$106 +3 +0.2%
Zurich Cantonal Bank
80
Zurich Cantonal Bank
Switzerland
$34K +$1.84K +52 +5%
PCM
81
Penserra Capital Management
California
$28K +$707 +20 +2%
SOW
82
State of Wyoming
Wyoming
$26K +$16K +454 +140%
Canada Life
83
Canada Life
Manitoba, Canada
$25K – – –
BNP Paribas Financial Markets
84
BNP Paribas Financial Markets
France
$23.9K -$123K -3,477 -83%
OSAM
85
O'Shaughnessy Asset Management
Connecticut
$22K – – –
Osaic Holdings
86
Osaic Holdings
Arizona
$10K – – –
FWM
87
FFT Wealth Management
Pennsylvania
$10K +$10.6K +300 New
EWM
88
Endurance Wealth Management
Rhode Island
$8K – – –
Simplex Trading
89
Simplex Trading
Illinois
$7K -$15.5K -439 -66%
CFGS
90
Concourse Financial Group Securities
Alabama
$7K – – –
QT
91
Quantbot Technologies
New York
$6K – – –
First Manhattan
92
First Manhattan
New York
$5K – – –
RE
93
RBC Europe
United Kingdom
$3.1K – – –
Daiwa Securities Group
94
Daiwa Securities Group
Japan
$2K – – –
IRC
95
Investors Research Corp
Georgia
$2K – – –
TFA
96
Toth Financial Advisory
Virginia
$2K – – –
AIG
97
American International Group
New York
$360 +$98.6K +2,790 +35%
ALSV
98
ATP Life Science Ventures
New York
– -$667M -17,161,713 Closed
Millennium Management
99
Millennium Management
New York
– -$3.09M -79,477 Closed
ACP
100
Acuta Capital Partners
California
– -$1.75M -45,000 Closed
1 2 3
4
5

STOK Hedge Fund Activity: Q2 2021 in Review

97 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2021, worth a combined $680M — down 54% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of STOK and 11 opened new positions — a net loss of 9 holders — while 26 trimmed existing stakes and 41 added.

The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $26.4M.

  • 97 institutional investors held Stoke Therapeutics (STOK) as of Q2 2021, down from 106 in Q1 2021.
  • Funds reported $680M of Stoke Therapeutics stock for Q2 2021, down 54% quarter-over-quarter.
  • 11 funds opened new Stoke Therapeutics positions in Q2 2021 and 20 closed out, a net change of -9 holders.
  • The largest Stoke Therapeutics buyer in Q2 2021 was Octagon Capital Advisors, an estimated $10.5M added.
  • The largest Stoke Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $26.4M sold.

Based on aggregated 13F filings for Q2 2021.